Date: Monday 19 April, 12-4.30pm
Venue: Online
Register: Here
Epigenetic modulators are attracting increasing interest as targets for pharmacotherapy across multiple therapy areas. This interactive event, hosted by the Cambridge Alliance on Medicines Safety, will focus on the safety challenges and toxicities associated with epigenetic modulation both inside and outside of an oncology setting. Representatives from AstraZeneca, GlaxoSmithKline and Novartis will provide an industry perspective of the regulatory and safety challenges currently faced when developing epigenetic dugs. Case studies will be used to highlight approaches currently taken within the pharmaceutical industry to assess the safety of epigenetic therapeutics, and the speakers will also discuss some of the fundamental challenges faced, and novel approaches to address these challenges. All are welcome to attend- please register to receive login details for this event.
